about
Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvementPatient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab.Have we overestimated the benefit of human(ized) antibodies?Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.Risk of cardiovascular disorders in psoriasis patients: current and future.Non-alcoholic fatty liver disease and psoriasis: So far, so near.The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries.At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibodyUstekinumab: moving the target from psoriasis to Crohn's disease.Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.Inhibitory effects of propofol on Th17 cell differentiation.The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews.Management of cutaneous disorders related to inflammatory bowel disease.5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland.European League against rheumatism - selected presentation and poster a highlights June 11th to 13th 2013.Human αβ and γδ T Cells in Skin Immunity and Disease.
P2860
Q30620977-DD88CDDD-B053-4376-BFD8-3421DA451F4EQ33800651-5830DA02-D87A-4A8D-85E0-4062F981A7F8Q34142714-4017D367-1145-4D1B-A528-6F0A99C42453Q34218639-6A2F71C9-9EC9-421D-90E0-0925F62FE8EFQ34323212-178FAA7E-791F-4CC0-8B1C-5B14D22DA792Q35237307-9EE96737-CD83-40A7-8597-C85D5D73B9F3Q35990756-E9AB9E52-7455-4A74-B477-D616942D0318Q36517187-CB58A2AC-8AAD-4F2E-8ED8-2409733FE69EQ38177321-96880BBC-1626-4F9C-970F-1257025FD758Q38394816-2329E45A-AD17-424B-A4EE-D3F9636EAC58Q38632657-A7F6C866-7715-41CC-97EB-B8B4FCEEB8F7Q38757761-173C4490-48AB-427D-9ACA-8BDF4DDDAA25Q39681190-8EE1E6A1-D41B-47DB-91C9-8C90C7DC08DDQ42406766-1345FB54-69F2-44A4-825C-044DE7233A64Q42869354-824E4B4A-C61B-4138-AEE0-8030CAD00E2EQ53309302-CFCEFF39-DAAB-4099-9637-8ECBC57B562AQ55265385-31EDB867-A337-4367-8B51-3566FB4AF76E
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Ustekinumab
@en
Ustekinumab
@nl
type
label
Ustekinumab
@en
Ustekinumab
@nl
prefLabel
Ustekinumab
@en
Ustekinumab
@nl
P2860
P3181
P356
P1476
Ustekinumab
@en
P2093
Oya Cingoz
P2860
P304
P3181
P356
10.4161/MABS.1.3.8593
P407
P50
P577
2009-05-01T00:00:00Z